STAT3 and breast carcinoma: Several STAT3 inhibitors have also entered clinical trials for obesity-linked cancers, including pancreatic cancer (phase III), metastatic colorectal cancer (phase II), ovarian cancer (phase II), hepatocellular carcinoma (phase I), and breast cancer (phase I) (37).